Nautilus Biotechnology appoints Karen Akinsanya, Schrödinger President, to Board

Nautilus Biotechnology, Inc.

Appointment effective March 30, 2022; Akinsanya will serve as Class III director through 2024.
Akinsanya is President of R&D, Therapeutics at Schrödinger and has 25+ years in drug discovery.
Director compensation: $40,000/year plus initial option award of 105,998 shares ($370K grant date FV).
She joins a board that includes leaders from genomics, cancer therapeutics, and tech (Illumina, Perceptive Advisors, etc.).

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Karen Akinsanya

Director

NAUT · Nautilus Biotechnology, Inc.

Effective: 2022-03-30
Filed: March 31, 2022, 7:59 PM ET

On March 30, 2022 , the board of directors (the “Board”) of Nautilus Biotechnology, Inc. (the “Company”), upon recommendation of the Nominating and Governance Committee of the Board, appointed Karen Akinsanya to the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Karen Akinsanya was appointed as Director at Nautilus Biotechnology, Inc..

Action: appointed
Role: Director

Exact text from the filing

On March 30, 2022 , the board of directors (the “Board”) of Nautilus Biotechnology, Inc. (the “Company”), upon recommendation of the Nominating and Governance Committee of the Board, appointed Karen Akinsanya to the Board, effective immediately.

View on SEC.gov

Nautilus Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001808805-22-000030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.